Mads Kreilgaard

Principal Scientist
Novo Nordisk A/S

Presentation(s):

• OC 50.5 - Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors

  Tuesday, July 12, 2022
  11:45 AM – 12:00 PM